Clinical- and ultrasound-based assessments may help distinguish between persistent inflammatory and non-inflammatory subtypes of difficult-to-treat psoriatic arthritis.

While the number of antimicrobial prescriptions increased during the first year after TNF inhibitor initiation in PsA, no rise in serious infections was observed.

In patients with psoriatic arthritis on combination targeted therapy, the risk for infections is not significantly different compared with those on standard therapy.